CommercialDocumentationMedium impact
08.00.25o, Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic Agents
Independence Blue Cross·Pulmonology, Cardiology, Internal Medicine·Pharmacy
Effective date
Apr 21, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.00.25o updates medical necessity criteria for pulmonary artery hypertension (PAH) treatment using intravenous, subcutaneous, and inhaled pharmacologic agents. This recent policy change (effective 04/21/2025) may affect prior authorization requirements, coverage determinations, and documentation standards for PAH drug therapies. Billing and clinical teams must review updated criteria to ensure claims comply with new medical necessity standards.
Action Required
By 04/21/2025: Billing team and clinical staff must obtain and review the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=04&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-00-25o to identify specific billing codes, prior authorization triggers, and medical necessity documentation requirements for PAH pharmacologic agents. Update billing system rules, prior authorization workflows, and provider encounter documentation templates accordingly. Communicate changes to all providers prescribing PAH medications. Claims submitted without compliance to updated medical necessity criteria will be denied.